Genmab A/S
GMAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $18,892 | $80,764 | $86,071 | $96,442 |
| - Cash | $1,761 | $8,213 | $8,213 | $9,858 |
| + Debt | $142 | $938 | $938 | $1,029 |
| Enterprise Value | $17,273 | $73,489 | $78,796 | $87,613 |
| Revenue | $1,022 | $5,862 | $715 | $6,441 |
| % Growth | -82.6% | 719.8% | -88.9% | – |
| Gross Profit | $964 | $5,501 | $673 | $6,104 |
| % Margin | 94.3% | 93.8% | 94.1% | 94.8% |
| EBITDA | $503 | $2,839 | $265 | $2,355 |
| % Margin | 49.2% | 48.4% | 37.1% | 36.6% |
| Net Income | $401 | $2,129 | $195 | $3,845 |
| % Margin | 39.2% | 36.3% | 27.3% | 59.7% |
| EPS Diluted | 0.65 | 3.42 | 0.31 | 5.99 |
| % Growth | -81% | 1,003.2% | -94.8% | – |
| Operating Cash Flow | $536 | $393 | $1,950 | $326 |
| Capital Expenditures | -$2 | -$63 | -$204 | -$27 |
| Free Cash Flow | $534 | $330 | $1,746 | $299 |